Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp)
AssigneeUniversity of South Florida
InventorDAVID L. VESELY
Life of this patent
Estimating the term…
Abstract
A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
Claims26
A method of modulating the growth of a cancer cell comprising the step of contacting at least one target cancer cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone.
A method of inhibiting the growth of a cancer cell comprising the steps of:
- contacting at least one target cancer cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone;
- and contacting the at least one target cell with an effective amount of at least one peptide hormone derived from the atrial natriuretic peptide prohormone.
A method of inhibiting the growth of a cancer cell comprising the steps of:
- contacting at least one target cancer cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone;
- and contacting the at least one target cell with an effective amount of a peptide hormone derived from the atrial natriuretic peptide prohormone, wherein the peptide hormone derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator peptide, and kaliuretic peptide, where the target cancer cell is selected from the group consisting of adenocarcinomas, sarcomas, small cell carcinoma and squamous cell carcinoma, and the effective amount of peptide hormone is administered in vivo to a person or animal.
A method of inhibiting the growth of a cancer cell comprising the steps of:
- contacting at least one target cancer cell with an effective amount of at least one intracellular mediator of a peptide hormone derived from the atrial natriuretic peptide prohormone;
- and contacting the at least one target cell with an effective amount of a combination of peptide hormones derived from the atrial natriuretic peptide prohormone, wherein the combination of peptide hormones derived from the atrial natriuretic peptide prohormone is selected from the group consisting of atrial natriuretic peptide, long acting natriuretic peptide, vessel dilator peptide, and kaliuretic peptide, and wherein the target cancer cell is chosen from the group consisting of adenocarcinoma, small cell carcinoma and squamous cell carcinoma, and the effective amount of the combination of peptide hormones is administered in vivo to a person or animal.
Dependencies are inferred from the claim text.